This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Induction Treatment Followed by Immunosuppression Withdrawal in Liver Transplantation: A Comparative Trial (ATEGE-LIVER)

This study has been terminated.
(Experimental arm (induction + low dose tacrolimus) not effective.)
Fresenius AG
Astellas Pharma Inc
Information provided by:
Hospital Clinic of Barcelona Identifier:
First received: February 16, 2007
Last updated: May 19, 2009
Last verified: May 2009
This is a randomized, controlled trial in liver transplantation in which conventional immunosuppressive treatment will be compared with a therapeutic strategy consisting in pre-transplant antibody-mediated T cell depletion followed by reduced calcineurin inhibitor usage. The working hypothesis is that antibody induction followed by calcineurin inhibitor minimization may promote development of tolerogenic mechanisms allowing the eventual withdrawal of all immunosuppressive therapy.

Condition Intervention Phase
Liver Diseases Drug: ATG (Fresenius Biotech) Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Study of ATEGE-Fresenius Induction in Liver Transplantation Followed by Tacrolimus Weaning.

Resource links provided by NLM:

Further study details as provided by Hospital Clinic of Barcelona:

Primary Outcome Measures:
  • Proportion of patients who can significantly decrease the doses of tacrolimus 1 year after transplantation (as defined by: tacrolimus administered on alternate days, or daily with trough levels below 5 ng/mL. [ Time Frame: 1 year ]

Secondary Outcome Measures:
  • Graft survival [ Time Frame: 1 year ]
  • Patient survival [ Time Frame: 1 year ]
  • Incidence of opportunistic infections [ Time Frame: 1 year ]
  • Incidence of acute/chronic rejection [ Time Frame: 1 year ]
  • Incidence of hypertension, renal failure, diabetes, hyperlipidemia [ Time Frame: 1 year ]

Estimated Enrollment: 72
Study Start Date: June 2006
Estimated Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: ATG (Fresenius Biotech)
    ATG-Fresenius 9 mg/kg at induction
    Other Names:
    • ATeGe
    • Anti-lymphocyte immunoglobulin
  Show Detailed Description


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age > 18 years
  • Recipient of a primary liver graft
  • Absence of any of our exclusion criteria

Exclusion Criteria:

  • Pretransplant renal failure, defined as serum creatinine > 1.5 mg/dL
  • Severe pretransplant thrombopenia, defined as platelets < 50000/mL
  • Combined liver-kidney transplantation
  • Autoimmune hepatitis, primary biliary cirrhosis or primary sclerosing cholangitis as causes of liver transplantation
  • Chronic hepatic encephalopathy
  • Living donor liver transplantation
  • Recipient with human immunodeficiency virus infection
  • Severe pretransplant leukopenia, defined as < 1500 leukocytes/mL
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00436722

Hospital Clinic Barcelona, University of Barcelona
Barcelona, Spain, 08036
Sponsors and Collaborators
Hospital Clinic of Barcelona
Fresenius AG
Astellas Pharma Inc
Principal Investigator: Alberto Sanchez-Fueyo Hospital Clinic Barcelona, Barcelona, Spain
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Miguel navasa, Hospital Clinic of Barcelona Identifier: NCT00436722     History of Changes
Other Study ID Numbers: EudraCT 2005-005635-10
Study First Received: February 16, 2007
Last Updated: May 19, 2009

Keywords provided by Hospital Clinic of Barcelona:
Liver transplantation

Additional relevant MeSH terms:
Liver Diseases
Digestive System Diseases
Antilymphocyte Serum
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Calcineurin Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on September 19, 2017